TMCnet News
SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmaceuticals, Inc.STEVENSON, Md. --(Business Wire)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Zalicus, Inc. ("Zalicus" or the "Company") (NasdaqCM: ZLCS) and other violations of state law by the board of directors of Zalicus relating to the proposed merger of the Company with Epirus Biopharmraceuticals, Inc. ("Epirus"). Under the terms of the transaction, the percentage of the combined company that Zalicus shareholders will own as of the closing of the merger is subject to an adjustment at closing based on the level of Zalicus net cash at closing. If the merger were to close today, he stockholders of Zalicus would own only 14% of the combined company. The firm's investigation seeks to determine, among other things, whether the Company's board of directors breached their fiduciary duties by failing to maximize shareholder value before agreeing to enter into this transaction, and whether Epirus is underpaying for Zalicus shares. If you currently own common stock of Zalicus and would like to learn more about the investigation being conducted by Brower Piven, without cost or obligation to you, click here: http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616. Attorneys at Brower Piven together have more than a century of experience litigating securities and other class action cases.
|
